Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy Bodies (DLB) is fully enrolled with topline data expected in December 2024

Join CervoMed for a virtual KOL event featuring John-Paul Taylor, MBBS (hons), MRCPsych, PhD (Newcastle University), who will discuss the unmet need and the role of loss of integrity of the cholinergic system in dementia with Lewy bodies (DLB), and Ralph A. Nixon, MD, PhD (New York University Grossman School of Medicine), who will focus on the mechanistic and preclinical data with neflamapimod, an oral p38α inhibitor that targets the molecular mechanisms underlying degeneration and dysfunction in the basal forebrain cholinergic system.

Agenda Topics: Right Disease, Right Drug, Right Patient, Right Trial

• Overview of the DLB disease state, unmet need and current treatment landscape for patients
• Understanding the role of the basal forebrain cholinergic system in clinical disease expression and progression in patients with DLB
• Neflamapimod mechanism of action and therapeutic potential to reverse disease progression in the basal forebrain cholinergic system
• Understanding the role of plasma phosphorylated tau in the selection of patients for inclusion in DLB clinical trials
• Overview of CervoMed’s Phase 2b RewinD-LB trial design in DLB, which is optimized for success and a positive result is expected to provide a clear path to market in this high value indication

A live question and answer session will follow the formal presentation.